Edition:
United Kingdom

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

1.21USD
12 Oct 2018
Change (% chg)

$0.03 (+2.54%)
Prev Close
$1.18
Open
$1.21
Day's High
$1.22
Day's Low
$1.14
Volume
24,419
Avg. Vol
72,242
52-wk High
$2.75
52-wk Low
$1.14

Chart for

About

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop... (more)

Overall

Beta: 2.44
Market Cap(Mil.): $94.42
Shares Outstanding(Mil.): 35.63
Dividend: --
Yield (%): --

Financials

  VSAR.OQ Industry Sector
P/E (TTM): -- 85.91 32.75
EPS (TTM): -3.45 -- --
ROI: -96.92 1.70 14.60
ROE: -100.35 3.17 16.33

BRIEF-Versartis Q1 Loss Per Share $0.25

* CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage:

08 May 2018

BRIEF-Versartis Says Board Approved Plan Of Termination To Eliminate A Number Of Positions Effective Oct 20, 2017

* VERSARTIS SAYS IN OCTOBER 2017, BOARD APPROVED PLAN OF TERMINATION TO ELIMINATE A NUMBER OF POSITIONS EFFECTIVE OCT 20, 2017 - SEC FILING

08 May 2018

Earnings vs. Estimates